Mesothelioma Cure - cancer cure lung mesothelioma

Mesothelioma Cure Detection by stage:

Mesothelioma Cure depends on where the cancer is, how far it has spread, and the patient's age and general health.

Standard Mesothelioma treatment may be considered because of its effectiveness in patients in past studies, or participation in a clinical trial may be considered. Not all patients are cured with standard therapy and some standard treatments may have more side effects than are desired. For these reasons, clinical trials are designed to find better ways to treat cancer patients and are based on the most up-to-date information. Clinical trials are ongoing in many parts of the country for many patients with malignant mesothelioma.

Stage I Mesothelioma Cure:

If the cancer is only in one place in the chest or abdomen, treatment will probably be surgery to remove part of the pleura and some of the tissue around it.

If the cancer is found in a larger part of the pleura, treatment may be one of the following:

1. Surgery to remove the pleura and the tissue near it to relieve symptoms, with or without radiation therapy after surgery.
2. Surgery to remove sections of the pleura, the lung, part of the diaphragm, and part of the lining around the heart.
3. External beam radiation therapy to relieve symptoms.
4. A clinical trial of surgery followed by chemotherapy given inside the chest.
5. A clinical trial of surgery, radiation therapy, and/or chemotherapy.

Stage II, III, IV Mesothelioma Cure:

Mesothelioma Cure may be one of the following:

1. Draining of fluid in the chest or abdomen (thoracentesis or paracentesis) to reduce discomfort. Drugs also may be put into the chest or abdomen to prevent further collection of fluid.
2. Surgery to relieve symptoms.
3. Radiation therapy to relieve symptoms.
4. Chemotherapy.
5. A clinical trial of surgery, radiation therapy, and chemotherapy.
6. Chemotherapy given in the chest or abdomen.

Recurrent malignant mesothelioma Cure:

Treatment depends on many factors, including where the cancer came back and what treatment the patient received before. Treatment of recurrent mesothelioma usually utilizes procedures and/or agents not previously employed in the initial treatment attempt. No standard treatment approaches have been proven to improve survival or control symptoms for a prolonged period of time. These patients should be considered candidates for phase I and II clinical trials evaluating new biologicals, chemotherapeutic agents, or physical approaches. Clinical trials are testing new treatments.

The safety and efficacy of pemetrexed, an antifolate, and cisplatin in chemotherapy-naive patients with malignant mesothelioma who were not eligible for curative surgery was demonstrated in a large phase III randomized trial. This trial compared pemetrexed (500 mg/m 2 ) and cisplatin (75 mg/m 2 on day 1) with cisplatin alone (75 mg/m 2 on day 1 intravenously every 21 days). A total of 456 patients were enrolled: 226 patients received pemetrexed plus cisplatin and 222 patients received cisplatin alone; 8 patients did not receive therapy. After 117 patients had enrolled, folic acid and vitamin B 12 were added to reduce toxic effects. Folic acid (350-1,000 µg orally) was given daily, beginning 1 to 3 weeks before the first chemotherapy dose and continuing daily until 1 to 3 weeks after treatment ended. A vitamin B 12 injection (1,000 µg intramuscularly) was administered 1 to 3 weeks before the first chemotherapy dose and was repeated approximately every 9 weeks until treatment ended. Dexamethasone (4 mg) or an equivalent corticosteroid was administered orally twice daily for skin rash prophylaxis to all patients 1 day before, on the day of, and 1 day after each pemetrexed dose.

In an analysis of all patients who were randomized and treated, the combination of pemetrexed and cisplatin was associated with a statistically significant improvement in survival compared with cisplatin alone; the median survivals were 12.1 versus 9.3 months, respectively (P=.020). The hazard ratio for death of patients in the pemetrexed plus cisplatin arm versus those in the control arm was 0.77. Median time to progression was significantly longer in the pemetrexed plus cisplatin arm (5.7 months vs 3.9 months, P=.001). This superiority in the combination arm was also demonstrated in the vitamin supplemented subgroup. The median survivals were 13.3 and 10.0 months in the combination group and cisplatin alone group, respectively (P=.051). The principal adverse effects of the pemetrexed plus cisplatin regimen were myelosuppression, fatigue, nausea, vomiting, and dyspnea. Most grade 3 to 4 adverse effects were significantly reduced by vitamin supplementation without any decrease in efficacy.

Cancer Tip Remember, there are hundreds, possibly thousands of cancer fighting phytochemicals in plants. If you just stick to a familiar few types, you’ll miss out on all the other cancer fighting phytochemicals that are found in the foods you don’t eat on a regular basis.

Become a regular visitor at our " Cancer Care Blog " - Here are the latest blog entries: Treatment for migraine Cancer Fighting Crucifers Is Common Sense or Research Needed to Cure Cancer? Surgical castration or bilateral orchidectomy Things Women Can Do to Prevent Cancer Things Men Can Do to Prevent Cancer

Health Tip Discovering new ways of communicating with someone after a stroke may do more than anything else to help the person.

Home . Mesothelioma . Mesothelioma Fact . Mesothelioma Asbestos . Mesothelioma Symptom . Mesothelioma Treatment . Mesothelioma Diagnosis . Mesothelioma Causes . Malignant Mesothelioma . Mesothelioma Stage . Pleural Mesothelioma . Mesothelioma Update . Asbestos . Asbestosis . Chemotherapy